Viridian Therapeutics, Inc. Common Stock

VRDN

...

VRDN: Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

Show VRDN Financials

All

Government

Consumer Interest

SEC Filings

ESG/Other

Congress Trading

Recent trades of VRDN by members of U.S. Congress

No Congress Trading data for this ticker

Congress Trading Dashboard

Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by VRDN's directors and management

Corporate Lobbying

Government lobbying spending instances

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

U.S. Patents

New patents grants

Patent Title: Compositions and methods for treatment of thyroid eye disease Jan. 10, 2023

Government Contracts

Federal grants, loans, and purchases

No Government Contracts for this ticker

Government Contracts Dashboard

Twitter

Followers on VRDN's company Twitter account

WallStreetBets

Number of mentions of VRDN in WallStreetBets Daily Discussion

VRDN News

Recent insights relating to VRDN

CNBC Recommendations

Recent picks made for VRDN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in VRDN

Corporate Flights

Flights by private jets registered to VRDN